$BPTH 6-bagger recovery volume Nasdaq CM $2.57 C
Post# of 63688
Posted On: 03/31/2016 11:22:23 AM
$BPTH 6-bagger recovery volume
Nasdaq CM $2.57
Called 9/21/13 $0.76
Website
Shares Outstanding: 89.76M
Float: 82.73M
% Held by Insiders: 8.59%
% Held by Institutions: 13.10%
Shares Short (as of Mar 15, 2016): 388.68K
Short Ratio (as of Mar 15, 2016): 3.94
Short % of Float (as of Mar 15, 2016): 0.47%
Shares Short (prior month): 352.60K
Headlines
Company Profile - Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase II study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Nasdaq CM $2.57
Called 9/21/13 $0.76
Website
Shares Outstanding: 89.76M
Float: 82.73M
% Held by Insiders: 8.59%
% Held by Institutions: 13.10%
Shares Short (as of Mar 15, 2016): 388.68K
Short Ratio (as of Mar 15, 2016): 3.94
Short % of Float (as of Mar 15, 2016): 0.47%
Shares Short (prior month): 352.60K
Headlines
Company Profile - Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase II study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
(0)
(0)Scroll down for more posts ▼